Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALOMA-3: palbociclib plus fulvestrant in HR-positive/HER2-negative metastatic breast cancer after prior endocrine therapy
2013-002580-26Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Palbociclib + fulvestrant ± goserelin with Placebo + fulvestrant ± goserelin (2 arms). Primary endpoint: Progression-Free Survival. Started Sep 2013; status: completed.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2013-002580-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002580-26.